It is noteworthy that afatinib, the second-line EGFR TKI, exhibits a significant inhibition on tumor growth in A431 xenograft model at the dose of 30 mg/kg (a clinically representative dose) (Supplementary Figure S3B), and the mice demonstrated severe body loss due to a poor selectivity of wild-type EGFR (Supplementary Figure S1C; Gurtner et al., 2014). The gene discussed is EGFR; the disease is neoplasm.